Efficacy of Treatment of Non-hereditary Angioedema.

Authors:
van den Elzen M; Go MFCL; Knulst AC; Blankestijn MA; van Os-Medendorp H and 1 more

Journal:
Clin Rev Allergy Immunol

Publication Year: 2018

DOI:
10.1007/s12016-016-8585-0

PMCID:
PMC6002429

PMID:
27672078

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Clin Rev Allergy Immunol

Abbreviation: Clin Rev Allergy Immunol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Autoinflammatory Keratinization Diseases-The Concept, Pathophysiology, and Clinical Implications.
Blicharz L; Czuwara J; Rudnicka L and 1 more (2023) - Transparency Score: 2/6
Environmental Risk Factors, Protective Factors, and Biomarkers for Allergic Rhinitis: A Systematic …
Xu X; Liu X; Li J and 5 more (2023) - Transparency Score: 4/6
Food Allergy Labeling Laws: International Guidelines for Residents and Travelers.
Chang F; Eng L; Chang C. (2023) - Transparency Score: 2/6
Advanced Imaging Supports the Mechanistic Role of Autoimmunity and Plaque Rupture in COVID-19 Heart…
Laino ME; Ammirabile A; Motta F and 7 more (2022) - Transparency Score: 2/6
A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification System…
Lazzaroni MG; Piantoni S; Angeli F and 3 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest M.T. van den Elzen has received speaker’s fees from Novartis. A.C. Knulst is a member of the national and international Novartis Omalizumab Advisory Council and has received speaker’s fees from Novartis and sponsoring for scientific studies from Novartis and Pharming. The rest of the authors declare that they have no relevant conflicts of interest."

Evidence found in paper:

"Funding None."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025